Effect of Vasopressors on Blood Thinning in Critically Ill Patients
Anti-Xa Activity in Patients Receiving Different Vasopressors.
This study is testing how different blood pressure medications affect blood thinning in critically ill patients who are getting a specific type of blood thinner to prevent clots.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Medical University of Gdansk Academic / other |
| Locations | 1 site (Gdańsk) |
| Trial ID | NCT06055907 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the impact of vasopressors, specifically norepinephrine with and without argipressin, on anti-Xa activity in critically ill patients receiving subcutaneous dalteparin for thrombosis prevention. The study aims to determine if there are differences in the effectiveness of anticoagulation between these two treatment groups. By measuring serum anti-Xa activity, the research seeks to provide insights into optimizing antithrombotic therapy in patients with circulatory failure. The findings could help tailor anticoagulation strategies in critical care settings.
Who should consider this trial
Good fit: Ideal candidates include critically ill patients experiencing circulatory failure who are receiving norepinephrine alone or in combination with argipressin and are on dalteparin for VTE prevention.
Not a fit: Patients with contraindications for dalteparin, severe coagulopathy, or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the safety and effectiveness of anticoagulation therapy in critically ill patients.
How similar studies have performed: While the specific approach of this study is novel, similar studies have explored the effects of vasopressors on anticoagulation, indicating potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Circulatory failure * Supported by continuous infusion of noradrenaline or noradrenaline and argipressin * Receiving subcutaneous dalteparin for the prevention of venous thromboembolism. Exclusion Criteria: * Contraindications for dalteparin * Severe coagulopathy * Acute or subacute bacterial endocarditis * Pregnant women * BMI (body mass index) \> 30kg/m2 * Chronic kidney disease with eGFR (estimated glomerular filtration rate) \< 30 ml/min/1.73 m2 * Renal replacement therapy * The patient died within 52 hours of starting VTE (venous thromboembolism) prophylaxis with dalteparin
Where this trial is running
Gdańsk
- Medical University of Gdańsk - Departament of Anesthesiology and Intensive Care — Gdańsk, Poland (Recruiting)
Study contacts
- Study coordinator: Jan Stefaniak, MD.
- Email: jan.stefaniak@gumed.edu.pl
- Phone: 505694054
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.